Skip to Content

  • Search

View Additional Section Content

Showing 1-3 of 3

Sorted By:

  • ECOG - S0438 - Randomized Phase II Trial of Bay 43-9006 ( Sorafenib; NSC-724772) with Either CCI-779 ( Temsirolimus; NSC-683864) or R115777 ( Tipifarnib; NSC-70218) in Metastatic Melanoma.

    Sorafenib, temsirolimus, and tipifarnib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib and tipifarnib may also stop the growth of tumor by blocking blood flow to the tumor. It is not yet known whether sorafenib is more effective when given together with temsirolimus or tipifarnib in treating patients with malignant melanoma. This randomized phase II trial is studying how well giving sorafenib together with either temsirolimus or tipifarnib works in treating patients with stage IV melanoma that cannot be removed by surgery. (NCT00281957)

  • ECOG E1608 – A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma.

    Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Colony-stimulating factors, such as sargramostim (GM-CSF), may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of treatment. It is not yet know whether giving ipilimumab together with GM-CSF is more effective than ipilimumab alone in treating melanoma. This randomized phase II trial is studying how well giving ipilimumab with or without sargramostim works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. (NCT01134614)

  • ECOG E1697 - Phase III Randomized Study of Four Weeks High Dose IFN-alpha2b in Stage T3-T4 or N1 (microscopic) Melanoma.

    Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery. (NCT00003641)

Showing trials 1-3 of 3

Clinical Trials Search Results